Sequencing Study from Roswell Park Highlights Previously Unknown Myeloma Resistance Mechanisms – Newswise

• First single-cell analysis in a prospective trial for patients with myeloma
• Plasma-cell clones responsible for characteristic bone lesions, team shows
• Findings suggest new strategies for eradicating minimal residual disease

Newswise — BUFFALO, N.Y. — A group of researchers led by Maximillian Merz, MD, Assistant Professor of Oncology with the Myeloma team at Roswell Park Comprehensive Cancer Center, conducted the first prospective clinical trial investigating spatial heterogeneity in patients with either…

Click here to view the original article.